Y H Kim1, S Y Park1, J Park1, Y S Kim1, E M Hwang2, J Y Park3, G S Roh1, H J Kim1, S S Kang1, G J Cho1, W S Choi4. 1. Department of Anatomy and Neurobiology, Medical Research Center for Neural Dysfunction, Institute of Health Science, School of Medicine, Gyeongsang National University, 92 Chilam-dong, Jinju, Gyeongnam, 660-751, Republic of Korea. 2. Center for Functional Connectomics, Korea Institute of Science and Technology, Seoul, Republic of Korea. 3. Department of Physiology, School of Medicine, Gyeongsang National University, Jinju, Republic of Korea. 4. Department of Anatomy and Neurobiology, Medical Research Center for Neural Dysfunction, Institute of Health Science, School of Medicine, Gyeongsang National University, 92 Chilam-dong, Jinju, Gyeongnam, 660-751, Republic of Korea. choiws@gnu.ac.kr.
Abstract
AIMS/HYPOTHESIS: The study aimed to evaluate the efficacy of recombinant adenovirus expressing αA-crystallin (Ad-αAc-Gfp) in reducing pericyte loss within retinal vasculature in early diabetes. METHODS: Diabetes was induced by streptozotocin injection into C57BL/6 mice. Ad-αAc-Gfp was delivered by intravitreous injection to the right eyes of mice 2 weeks before induction of diabetes. Vascular leakage was determined by fluorescent angiography, Evans Blue leakage assay and leucocyte adhesion test. Production of αA-crystallin was analysed by immunoblotting and double immunostaining and pericyte loss was analysed by pericyte count. RESULTS: Vessel leakage and pericyte loss were observed in the streptozotocin-induced diabetic retina. Decreased abundance of αA-crystallin in retinas 2 and 6 months after the induction of diabetes was confirmed by two-dimensional electrophoretic analysis, immunoblotting and RT-PCR. Double immunofluorescence staining for αA-crystallin and NG2 chondroitin sulphate proteoglycan revealed that αA-crystallin was predominantly produced in the retinal pericyte and that the number of αA-crystallin-producing pericytes decreased in the diabetic retina. Retinal infection with Ad-αAc-Gfp led to decreased pericyte loss and vascular leakage compared with control. CONCLUSIONS/ INTERPRETATION: Intravitreal delivery of Ad-αAc-Gfp protects against vascular leakage in the streptozotocin-induced model of diabetes. This effect is associated with the inhibition of diabetic retinal pericyte loss in early diabetes, suggesting that αA-crystallin has a role in preventing the pathogenesis of early diabetic retinopathy.
AIMS/HYPOTHESIS: The study aimed to evaluate the efficacy of recombinant adenovirus expressing αA-crystallin (Ad-αAc-Gfp) in reducing pericyte loss within retinal vasculature in early diabetes. METHODS:Diabetes was induced by streptozotocin injection into C57BL/6 mice. Ad-αAc-Gfp was delivered by intravitreous injection to the right eyes of mice 2 weeks before induction of diabetes. Vascular leakage was determined by fluorescent angiography, Evans Blue leakage assay and leucocyte adhesion test. Production of αA-crystallin was analysed by immunoblotting and double immunostaining and pericyte loss was analysed by pericyte count. RESULTS: Vessel leakage and pericyte loss were observed in the streptozotocin-induced diabetic retina. Decreased abundance of αA-crystallin in retinas 2 and 6 months after the induction of diabetes was confirmed by two-dimensional electrophoretic analysis, immunoblotting and RT-PCR. Double immunofluorescence staining for αA-crystallin and NG2chondroitin sulphate proteoglycan revealed that αA-crystallin was predominantly produced in the retinal pericyte and that the number of αA-crystallin-producing pericytes decreased in the diabetic retina. Retinal infection with Ad-αAc-Gfp led to decreased pericyte loss and vascular leakage compared with control. CONCLUSIONS/ INTERPRETATION: Intravitreal delivery of Ad-αAc-Gfp protects against vascular leakage in the streptozotocin-induced model of diabetes. This effect is associated with the inhibition of diabetic retinal pericyte loss in early diabetes, suggesting that αA-crystallin has a role in preventing the pathogenesis of early diabetic retinopathy.
Authors: Peter A Campochiaro; Quan Dong Nguyen; Syed Mahmood Shah; Michael L Klein; Eric Holz; Robert N Frank; David A Saperstein; Anurag Gupta; J Timothy Stout; Jennifer Macko; Robert DiBartolomeo; Lisa L Wei Journal: Hum Gene Ther Date: 2006-02 Impact factor: 5.695
Authors: Y H Kim; I Y Chung; M Y Choi; Y S Kim; J H Lee; C H Park; S S Kang; G S Roh; W S Choi; J M Yoo; G J Cho Journal: Neurobiol Dis Date: 2007-02-09 Impact factor: 5.996
Authors: Pedro Geraldes; Junko Hiraoka-Yamamoto; Motonobu Matsumoto; Allen Clermont; Michael Leitges; Andre Marette; Lloyd P Aiello; Timothy S Kern; George L King Journal: Nat Med Date: 2009-11-01 Impact factor: 53.440
Authors: L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 1994-01 Impact factor: 4.799
Authors: Narsing A Rao; Sindhu Saraswathy; Guey Shuang Wu; George S Katselis; Eric F Wawrousek; Suraj Bhat Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Ram H Nagaraj; Rooban B Nahomi; Niklaus H Mueller; Cibin T Raghavan; David A Ammar; J Mark Petrash Journal: Biochim Biophys Acta Date: 2015-04-01
Authors: Vivian Rajeswaren; Jeffrey O Wong; Dana Yabroudi; Rooban B Nahomi; Johanna Rankenberg; Mi-Hyun Nam; Ram H Nagaraj Journal: Front Mol Biosci Date: 2022-04-11
Authors: Rooban B Nahomi; Benlian Wang; Cibin T Raghavan; Oliver Voss; Andrea I Doseff; Puttur Santhoshkumar; Ram H Nagaraj Journal: J Biol Chem Date: 2013-03-18 Impact factor: 5.157